cgreene
commented
4 years ago I edited since the formatting was messed up. Looks like we had an unclosed comment tag in our template. I'll fix it in the PR I send to @SiminaB's repo that should land later today.
cbrueffer
Title: A human monoclonal antibody blocking SARS-CoV-2 infection
Please paste a link to the paper or a citation here: https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf
https://doi.org/10.1101/2020.03.11.987958
Is this paper primarily relevant to Background, Diagnostics, or Therapeutics? (OK if more than one) Relevant to Therapeutics and Diagnostics
Please list some keywords (3-10) that help identify the relevance of this paper to COVID-19
Neutralizing antibodies, SARS-CoV-2 glycoproteins, Receptor-binding-interference,
Suggested questions to answer about each paper:
Antibody binding to SARS-CoV-2 surface glycoprotein
Inhibition of infection by SARS-CoV-2 using the neutralizing antibody
Binding affinities for various spike protein domains
What methods did they use? Immunofluorescence, Flow-cytometry, Neutralization assays, ELIZA, Hybridoma antibody generation,
Does this paper study COVID-19, SARS-CoV-2, or a related disease and/or virus? Yes
What is the main finding (or a few main takeaways)?
Generation of a humanized monoclonal antibody against SARS-CoV-2
Mechanism of action unknown but distinct from ACE2 receptor binding interference
The antibody may be useful for diagnostics (antigen detection) and therapeutics
What does this paper tell us about the background and/or diagnostics/therapeutics for COVID-19 / SARS-CoV-2? No approved targeted therapy available to date, Background about the emergence of the disease, Structural biology of the spike proteins,
Do you have any concerns about methodology or the interpretation of these results beyond this analysis?
Only in vitro, no in vivo validation
Any comments or notes?
Neutralizing concentration in vitro is relatively high